Status:

WITHDRAWN

Coronavirus Smell Therapy for Anosmia Recovery

Lead Sponsor:

Washington University School of Medicine

Conditions:

Anosmia

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

As the COVID-19 pandemic spread around the world, anosmia and dysgeusia were quickly recognized as two of the key presenting symptoms. The probability of return of smell is related to severity of smel...

Detailed Description

This will be a virtual or "contactless" clinical trial. Subjects will be recruited through a variety of ways and will complete all baseline and post-intervention assessments via specially designed ele...

Eligibility Criteria

Inclusion

  • Adult women and men.
  • Positive laboratory finding for SARS-CoV-2 (e.g., real-time reverse-transcription polymerase chain reaction (rRT-PCR) assays to detect viral RNA).
  • In convalescence from their COVID-19 illness.
  • Subjective complaints of reduced olfaction after COVID-19 infection of greater than 3 months duration.
  • Reduced olfaction ability as determined by a score of \<35 (women) or \<34 (men) on the University of Pennsylvania Smell Identification Test (UPSIT ).
  • Ability to read, write, and understand English.

Exclusion

  • History of olfaction disorder prior to COVID-19 infection.
  • History of nasal cavity polyps.
  • Dependence on prolonged corticosteroid therapy for comorbid conditions, such as asthma and chronic obstructive pulmonary disease.
  • History of cerebrospinal fluid leak.
  • History of allergy to budesonide or other topical steroids.
  • Pregnant or breast feeding or intend to become pregnant during the course of the trial.
  • Current infection or history of one of the following infections: Tuberculosis (TB) lung infection, or Herpes infection of the eye.
  • Baseline UPSIT score 5 or below, which suggests malingering.
  • History of neurodegenerative disease (i.e. Alzheimer's dementia, Parkinson's disease, Lewy body dementia, frontotemporal dementia).

Key Trial Info

Start Date :

June 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04422275

Start Date

June 1 2021

End Date

December 31 2023

Last Update

March 2 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Washington University

St Louis, Missouri, United States, 63110